Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03751488 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

A Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Luye Pharma Group.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
2
Study locations

NCT03751488 is a Phase 1 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Luye Pharma Group. The registered enrollment target is 48 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03751488, a Phase 1 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Luye Pharma Group.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

Conditions Studied

Schizophrenia Schizoaffective Disorder Schizo Affective Disorder

Interventions

  • DRUG LY03010
  • DRUG Invega Sustenna 156 MG in 1 ML Prefilled Syringe

Study Locations (2)

California

  • Collaborative Neuroscience Network LLC - Garden Grove

New Jersey

  • Hassman Research Institute - Berlin

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2018-12-12
Est. Completion 2019-07-24
Phase Phase 1

Sponsor

Luye Pharma Group

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03751488

The ClinicalTrials.gov registry entry for NCT03751488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (78% lower). The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which LY03010 is the first listed.

NCT03751488 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03751488 about?

NCT03751488 is a clinical study titled "A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients". This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

What is the current status of trial NCT03751488?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-12-12. Estimated completion is 2019-07-24.

What conditions does trial NCT03751488 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Schizo Affective Disorder.

What interventions are being tested in trial NCT03751488?

The interventions under investigation include: LY03010 (DRUG), Invega Sustenna 156 MG in 1 ML Prefilled Syringe (DRUG).

Who is sponsoring clinical trial NCT03751488?

This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03751488 being conducted?

This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Schizoaffective Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.